Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis by Makarov, Vadim et al.
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking
Arabinan Synthesis
Vadim Makarov1,2,*, Giulia Manina1,3,*, Katarina Mikusova1,4,*, Ute Möllmann1,5,*, Olga
Ryabova1,2, Brigitte Saint-Joanis1,6, Neeraj Dhar7, Maria Rosalia Pasca1,3, Silvia Buroni1,3,
Anna Paola Lucarelli1,3, Anna Milano1,3, Edda De Rossi1,3, Martina Belanova1,4, Adela
Bobovska1,4, Petronela Dianiskova1,4, Jana Kordulakova1,4, Claudia Sala1,7, Elizabeth
Fullam1,7, Patricia Schneider1,7, John D. McKinney7, Priscille Brodin8, Thierry Christophe8,
Simon Waddell1,9, Philip Butcher1,9, Jakob Albrethsen1,10, Ida Rosenkrands1,10, Roland
Brosch1,6, Vrinda Nandi1,11, Sowmya Bharath1,11, Sheshagiri Gaonkar1,11, Radha K.
Shandil1,11, Venkataraman Balasubramanian1,11, Tanjore Balganesh1,11, Sandeep Tyagi12,
Jacques Grosset12, Giovanna Riccardi1,3, and Stewart T. Cole1,7,†
1New Medicines for Tuberculosis (NM4TB) Consortium (www.nm4tb.org) 2A. N. Bakh Institute of
Biochemistry, Russian Academy of Science, 119071 Moscow, Russia 3Dipartimento di Genetica
e Microbiologia, Università degli Studi di Pavia, via Ferrata, 1, 27100 Pavia, Italy 4Department of
Biochemistry, Faculty of Natural Sciences, Comenius University, Mlynska dolina, 84215
Bratislava, Slovakia 5Department of Molecular and Applied Microbiology, Leibniz Institute for
Natural Product Research and Infection Biology–Hans Knoell Institute, Beutenbergstrasse 11a,
D-07745 Jena, Germany 6Institut Pasteur, Integrated Mycobacterial Pathogenomics, 25-28, Rue
du Docteur Roux, 75724 Paris Cedex 15, France 7Global Health Institute, Ecole Polytechnique
Fédérale de Lausanne, CH-1015 Lausanne, Switzerland 8Inserm Avenir Group, Institut Pasteur
Korea, 39-1 Hawolgok-dong, Seongbukgu, 136-791 Seoul, Korea 9Division of Cellular and
Molecular Medicine, St. George’s Hospital, University of London, Cranmer Terrace, SW17 ORE
London, UK 10Statens Serum Institut, Department of Infectious Disease Immunology, Artillerivej
5, DK-2300 Copenhagen S, Denmark 11AstraZeneca India, Bellary Road Hebbal, Bangalore,
India 12Center for Tuberculosis Research, Johns Hopkins University School of Medicine,
Baltimore, MD 21231, USA
Abstract
New drugs are required to counter the tuberculosis (TB) pandemic. Here, we describe the
synthesis and characterization of 1,3-benzothiazin-4-ones (BTZs), a new class of
antimycobacterial agents that kill Mycobacterium tuberculosis in vitro, ex vivo, and in mouse
models of TB. Using genetics and biochemistry, we identified the enzyme decaprenylphosphoryl-
β-D-ribose 2′-epimerase as a major BTZ target. Inhibition of this enzymatic activity abolishes the
formation of decaprenylphosphoryl arabinose, a key precursor that is required for the synthesis of
the cell-wall arabinans, thus provoking cell lysis and bacterial death. The most advanced
compound, BTZ043, is a candidate for inclusion in combination therapies for both drug-sensitive
and extensively drug-resistant TB.
The loss of human lives to tuberculosis (TB) continues essentially unabated as a result of
poverty, synergy with the HIV/AIDS pandemic, and the emergence of multidrug- and
extensively drug-resistant strains of Mycobacterium tuberculosis (1-3). Despite some recent
successes, such as the discovery of the diarylquinoline drug TMC207 (4) and the promise of
the bicyclic nitroimidazole compounds (5-8), and because of the high attrition rate in drug
development (9), much greater effort is required to find better drugs in order to meet the
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desired goals of killing persistent tubercle bacilli and reducing TB treatment duration from 6
to less than 3 months (10, 11).
A series of sulfur-containing heterocycles was synthesized and tested for antibacterial and
antifungal activity (12, 13). Among their derivatives, compounds belonging to the
nitrobenzothiazinone (BTZ) class showed particular promise in terms of their potency and
specificity for mycobacteria. One of them, 2-[2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-
yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (BTZ038), was selected for
further studies. This compound (series number 10526038; C17H16F3N3O5S, with a
molecular weight of 431.4; logP =2.84) (Fig. 1A) was synthesized in seven steps with a
yield of 36%. Structure activity relationship work showed that the sulfur atom and the nitro
group at positions 1 and 8, respectively, were critical for activity. BTZ038 has a single chiral
center, and both enantiomers, BTZ043 (S) and BTZ044 (R), were found to be equipotent in
vitro. Because early metabolic studies with bacteria or mice indicated that the nitro group
could be reduced to an amino group, and because many TB drugs are prodrugs that require
activation by M. tuberculosis (14), the S and R enantiomers of the amino derivatives and the
likely hydroxylamine intermediate were synthesized and tested for antimycobacterial
activity in vitro (table S1). The amino (BTZ045, S and R) and hydroxylamine (BTZ046)
derivatives were substantially less active (500- to 5000-fold).
The minimal inhibitory concentrations (MICs) of a variety of BTZs against different
mycobacteria were very low, ranging from ~0.1 to 80 ng/ml for fast growers and from 1 to
30 ng/ml for members of the M. tuberculosis complex (13). The MIC of BTZ043 against M.
tuberculosis H37Rv and Mycobacterium smegmatis were 1 ng/ml (2.3 nM) and 4 ng/ml (9.2
nM), respectively (Table 1), which compares favorably with those of the existing TB drugs
isoniazid (INH) (0.02 to 0.2 μg/ml) and ethambutol (EMB) (1 to 5 μg/ml) (14). From
structure activity relationship studies, >30 different BTZ derivatives showed MICs of <50
ng/ml against tubercle bacilli (examples are shown in table S2). Crucially, BTZ043
displayed similar activity against all clinical isolates of M. tuberculosis that were tested,
including multidrug-resistant and extensively drug-resistant strains, indicating that it targets
a previously unknown biological function (table S3). BTZ043 is bactericidal, reducing
viability in vitro by more than 1000-fold in under 72 hours (Fig. 1B), which is comparable
to the killing effect seen with INH. In two different model systems (auxotrophy and
starvation) involving metabolically inert M. tuberculosis, BTZ043 was less effective, which
implies that it blocks a step in active metabolism, similar to INH (14).
Observation with time-lapse fluorescence microscopy of individual M. smegmatis cells
[expressing green fluorescent protein (GFP)] growing in a microfluidic device (15) revealed
that upon exposure to BTZ043, the growth rate decreased rapidly followed by a swelling of
the poles and lysis of the cells after a few hours (movie S1). M. tuberculosis showed similar
but delayed behavior (movie S2 and fig. S1).
Comparative transcriptome analysis of M. tuberculosis offered no evidence of mutagenic or
nitrosative gene expression signatures after treatment with BTZ043, although expression of
60 genes was induced (table S4), and this was corroborated with proteomics. The
transcriptional signature most resembled that generated by the cell wall inhibitors INH,
isoxyl, and ethionamide, with the greatest overlap seen with the response to EMB treatment
(16, 17). This is consistent with cell lysis and indicated that BTZ targets cell wall
biogenesis.
We then tested the uptake, intracellular killing, and potential cytotoxicity of BTZ
compounds in an ex vivo model using a high-content screening approach (18, 19) in order to
monitor macrophages infected with M. tuberculosis expressing GFP. Macrophages treated
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with BTZ043 were protected (fig. S2) as compared with those treated with the amino
derivative BTZ045 or the negative controls [dimethyl sulfoxide (DMSO)]. The deduced
MIC of BTZ043 was <10 ng/ml, indicating that this compound is more potent than INH
(100 ng/ml) and rifampin (>1 μg/ml) against intracellular bacteria (Fig. 1C). In contrast, the
amino metabolite BTZ045 had an MIC of >1μg/ml, which is consistent with the in vitro
findings (table S1). As a direct correlate of the antibacterial effect, there was extensive
macrophage survival when all compounds were used at doses well above the MIC. BTZ043
was more cytotoxic than INH (Fig. 1C) at the highest concentration tested (10 μg/ml) but
nonetheless has a favorable selectivity index of >100. Additional in vitro toxicology tests
revealed no particularly unfavorable effects (table S4).
The in vivo efficacy of BTZ043 was assessed 4 weeks after a low-dose aerosol infection of
BALB/c mice in the chronic model of TB. Four weeks of treatment with BTZ043 reduced
the bacterial burden in the lungs and spleens by 1 and 2 logs, respectively, at the
concentrations used (Fig. 1D). Additional results suggest that BTZ efficacy is time- rather
than dose-dependent. Acute (5 g/kg) and chronic (25 and 250 mg/kg) toxicology studies in
uninfected mice showed that, even at the highest dose tested, there were no adverse
anatomical, behavioral, or physiological effects after one month (table S5).
To find the target for BTZ, we employed two independent genetic approaches. First, we
identified cosmids bearing DNA from M. smegmatis that confer increased resistance on M.
smegmatis, and we pinpointed the region responsible by subcloning. Second, we isolated
and characterized mutants of M. smegmatis, M. bovis Bacille Calmette-Guérin (BCG), and
M. tuberculosis displaying high-level BTZ resistance. The first approach revealed that the
MSMEG_6382 gene of M. smegmatis or its M. tuberculosis ortholog rv3790 mediated
increased resistance (Fig. 2A), whereas the second showed that drug-resistant mutants
harbor missense mutations in the same gene (Table 1). Biochemical studies showed that
rv3790 and the neighboring gene rv3791 code for proteins that act in concert to catalyze the
epimerization of decaprenylphosphoryl ribose (DPR) to decaprenylphosphoryl arabinose
(DPA) (20), a precursor for arabinan synthesis without which a complete mycobacterial cell
wall cannot be produced. These essential membrane-associated enzymes (20-23) have been
suggested to act as decaprenylphosphoryl-β-D-ribose oxidase and decaprenylphosphoryl-D-2-
keto erythro pentose reductase, respectively, and we propose naming them DprE1 and
DprE2. In all of the drug-resistant mutants we examined, the same codon of rv3790 (dprE1)
was affected, in which Cys387 was replaced by Ser or Gly codons, respectively (Table 1).
Mutants, harboring alleles such as those in MN47 or MN84, were rare, arising at a
frequency of <10−8, and were dominant over the wild-type gene upon introduction into a
BTZ-susceptible mycobacterium. Comparative genomics revealed that the BTZ resistance–
determining region of rv3790 was highly conserved in orthologous genes from various
actinobacteria, except that in a few cases Cys387 was replaced by Ser or Ala (Fig. 2B). The
corresponding bacteria, M. avium and M. aurum, were found to be naturally resistant to
BTZ (table S3), thus supporting the identification of DprE1/Rv3790 as the target.
Further corroboration was obtained biochemically (Fig. 3) by using membrane preparations
from M. smegmatis to catalyze the epimerization reaction from radiolabeled DPR precursor,
which was produced in situ from 5-phosphoribose diphosphate (20), in the presence or
absence of BTZ. Addition of BTZ038, or its enantiomers BTZ043 and BTZ044, abolished
the production of DPA from DPR. This reaction was scarcely affected by either the S or R
forms of BTZ045 (Fig. 3A) or by BTZ046 (fig. S3). Using recombinant proteins, we found
that the reaction requires both DprE1 and E2 (Rv3790 and Rv3791) (Fig. 3B), with neither
enzyme alone capable of catalyzing DPA formation. Furthermore, when BN2, the highly
BTZ-resistant mutant of M. bovis BCG, or M. smegmatis MN47 and MN84, with missense
mutations in MSMEG_6382 (dprE1) (Table 1), were used as sources of enzymes,
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epimerization was no longer subject to inhibition (Fig. 3C and fig. S3), thereby confirming
identification of the BTZ target.
The point of BTZ inhibition in the biosynthetic pathway for arabinan precursors is shown in
fig. S4, and as predicted by the gene expression profiling results, BTZ and EMB both target
the same pathway, which is restricted to certain actinobacteria. The latter drug acts
downstream on the EmbCAB arabinosyl transferases that use DPA, the sole arabinan donor
in mycobacteria, to produce arabinogalactan or lipoarabinomannan (24, 25). Consistent with
DPA limitation, BTZ treatment also blocks the production of both of these species (fig. S3).
Arabinogalactan plays a critical function in the mycobacterial cell envelope by acting as a
covalent linker between peptidoglycan on the inside and the mycolic acids at the outer
surface, thus playing a pivotal role in cellular integrity. A major difference between the two
drugs lies in the potency of BTZ, which is 1000-fold more active than EMB against M.
tuberculosis.
In conclusion, BTZ is a candidate for development into a sterilizing TB drug acting on the
enzyme decaprenylphosphoryl-β-D-ribose 2′-epimerase. This target has been chemically
validated in vivo and can now be used in screening for the identification of additional
inhibitors.
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Fig. 1.
Comparative BTZ efficacy in in vitro, ex vivo, and mouse models. (A) Structure of BTZ038.
The chiral center involves the methyl group at right. (B) Kill-kinetics in batch culture
showing a decrease in viability of M. tuberculosis H37Rv in 7H9 medium containing
BTZ043 in comparison with INH (both at 200 ng/ml). The regrowth after treatment with
INH (pound sign indicates the experiment was terminated because of resistance) is not seen
with BTZ043. (C) Response of macrophages infected with GFP-labeled M. tuberculosis to
treatment with different compounds, expressed in percent of bacterial load (triangles), cell
survival (circles), and infected cells (squares) relative to compound concentration in grams
per milliliter. Each percentage is based on DMSO and INH controls from the same
experiments. For each concentration, the mean ± SEM of the quadruplicate are reported. For
the original images, see fig. S2. (D) Efficacy of BTZ043 in a mouse model of chronic
tuberculosis compared with INH, rifampin (RIF), and untreated controls. Red and black
columns correspond to the bacterial load in the lungs and spleens, respectively, of
chronically infected BALB/c mice (4 weeks after infection) at day 0 (D0), before treatment.
The remaining columns show bacterial loads at day 28 in untreated animals (NT) (5 per
group) or in mice treated with various drugs at the doses indicated (milligrams per kilogram
of body weight per day). Bars represent the mean ± SEM; data are representative of two
independent experiments from two different centers. **P = 0.001; ***P < 0.000001.
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Fig. 2.
Identification of the BTZ target. (A) Organization of genomic regions of M. tuberculosis and
M. smegmatis associated with BTZ resistance. (B) Multiple alignment of the BTZ
resistance–determining region in orthologs of Rv3790 from various actinobacteria.
Makarov et al. Page 7
Science. Author manuscript; available in PMC 2011 July 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Fig. 3.
Inhibition of decaprenylphosphoryl-β-D-ribose epimerization by BTZ. (A) Effect of different
BTZ derivatives (table S1) on DPA production from DPR by using mycobacterial
membranes in vitro. Lane 1, no drug control; lane 2, BTZ038; lane 3, BTZ043; lane 4,
BTZ044; lane 5, BTZ045S; lane 6, BTZ045R. (B) Production of DPA from DPR requires
both Rv3790 (DprE1) and Rv3791 (DprE2). E. coli strains that were used in the experiment
(26) expressed the following M. tuberculosis proteins: lane 1, none; lane 2, Rv3790-Rv3791;
lane 3, none; lane 4, Rv3791; lane 5, none; lane 6, Rv3790; lane 7, none; lane 8, Rv3790.
(C) Effect of BTZ043 on DPA production by using cell wall fractions from BTZ-sensitive
M. bovis BCG and its BTZ-resistant mutant, BN2 (Table 1).
26Materials and methods are available as supporting material on Science Online.
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